First‐in‐human safety, tolerability, and pharmacokinetic results of DFV890, an oral low‐molecular‐weight NLRP3 inhibitor.
Saved in:
| Title: | First‐in‐human safety, tolerability, and pharmacokinetic results of DFV890, an oral low‐molecular‐weight NLRP3 inhibitor. |
|---|---|
| Authors: | Gatlik, Ewa1 (AUTHOR), Mehes, Beata1 (AUTHOR), Voltz, Emilie1 (AUTHOR), Sommer, Ulrike1 (AUTHOR), Tritto, Elaine1 (AUTHOR), Lestini, Giulia2 (AUTHOR), Liu, Xiaoxi3 (AUTHOR), Pal, Parasar4 (AUTHOR), Velinova, Maria5 (AUTHOR), Denney, Wiliam S.6 (AUTHOR), Fu, Yunlin3 (AUTHOR), Opipari, Anthony7 (AUTHOR), Dean, Dennis7 (AUTHOR), Junge, Guido1 (AUTHOR) guido.junge@novartis.com |
| Source: | CTS: Clinical & Translational Science. May2024, Vol. 17 Issue 5, p1-16. 16p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
